[
    {
        "pregunta": "1. What are the key recommendations for perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty according to the 2022 American College of Rheumatology guideline?",
        "respuesta": "The 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline provides recommendations for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. While the provided excerpt does not list specific recommendations, it mentions that the guideline addresses the management of disease-modifying medications for patients with inflammatory arthritis (such as spondylarthritis, rheumatoid arthritis, or psoriatic arthritis) and systemic lupus erythematosus. \n\nThe guideline takes into account the increased risk of infection and potentially higher risk of perioperative cardiac and/or thromboembolic events that these patients might face. However, the exact specific recommendations for each antirheumatic medication are not detailed in the provided information. Further consultation of the full guideline document would be necessary to obtain detailed recommendations for each antirheumatic drug.",
        "contexto": [
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty      32D6EF0B25CDA1FB80B29547C7367EA8 10.1002/acr.24893  This updated guideline addresses the perioperative management of disease modifying medications for adults with rheumatic diseases, specifically inflammatory arthritis (IA) and systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) and total knee arthroplasty (TKA). A panel of rheumatologists, orthopaedic surgeons, and infectious disease specialists updated the systematic literature review and included currently available medications for the clinically relevant population, intervention, comparator, and outcomes (PICO) questions, updating the 2017 recommendations*. As patients with IA and SLE are at increased risk of infection after THA and TKA, these",
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty  American College of Rheumatology      D7E914B32636437769C151DE0A277789 10.1002/acr.24893 Submitted for publication February 9, 2022; accepted in revised form April 7, 2022.  INTRODUCTION Advances in antirheumatic therapy have led to remarkable improvements in treatment and quality of life for people with rheumatic musculoskeletal diseases (RMDs); however, total hip arthroplasty (THA) and total knee arthroplasty (TKA) remain a mainstay of treatment among RMD patients with advanced symptomatic joint damage, most frequently those with inflammatory arthritis (IA), including spondylarthritis (SpA), rheumatoid arthritis (RA), or psoriatic arthritis (PsA), and those with systemic lupus erythematosus (SLE) The optimal strategy for perioperative",
            "be at potentially higher risk of perioperative cardiac and/or thromboembolic events. Therefore, consideration of the role of comorbidities and the interaction with antirheumatic therapy should also be pursued. In summary, this guideline provides an update to the ACR/AAHKS 2017 guideline to provide clinicians and patients information about risks and benefits regarding management of perioperative antirheumatic medication to inform decisions prior to THA and TKA. We have updated our evidence base through our search of the current literature and assessed that information through the lens of our clinical expertise and the perspectives of the patients who have participated in this process. We acknowledge the gaps in our information base and intend to continue to fill those gaps as more research is available. ACR/AAHKS GUIDELINE FOR PERIOPERATIVE MANAGEMENT    Supported by the American College of Rheumatology American Association of Hip and Knee Surgeons",
            "<h1>RESULTS/RECOMMENDATIONS</h1>\n\n<h1>Table 3. Recommendations for perioperative management of anti-rheumatic drug therapy in patients with inflammatory arthritis and those with systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA)*</h1>",
            "disease activity and are likely to be taking immunosuppressant medications at the time of surgery, the management of which was felt to be beyond the scope of this guideline. This was the focus of the 2022 American College of Rheumatology (ACR)/American Association of Hip and Knee Surgeons (AAHKS) Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty METHODS This guideline follows the ACR guideline development process and ACR policy guiding management of conflicts of interest and disclosures https://rheumatology.org/clinicalpractice-guidelines Consensus required ≥70% agreement on both direction (for or against) and strength (strong or conditional) of each recommendation, as per ACR practice. A recommendation could be either in favor of or against the proposed intervention and either strong or conditional. According to GRADE, a recommendation was categorized as strong if the"
        ]
    },
    {
        "pregunta": "2. Why are all recommendations in the guideline considered conditional?",
        "respuesta": "The 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for perioperative management of antirheumatic medication in patients undergoing elective total hip or total knee arthroplasty considers all recommendations as conditional. This is because a conditional recommendation implies that the guideline panel believes the majority of informed patients would choose the recommended course of action, but there is an appreciable minority who would not. This reflects the emphasis on individual patient preferences and the need for a shared decision-making process that accounts for patient-specific risks and benefits. The guideline underscores the importance of considering patient preferences and individualized risk estimates to determine the appropriate course of action.",
        "contexto": [
            "arthroplasty for patients who have rheumatic diseases, as they were the focus of the recent ACR/AAHKS guideline for the perioperative management of antirheumatic medications in patients undergoing total hip and total knee arthroplasty A conditional recommendation means that the panel has inferred that the majority of informed patients would choose the recommended course of action, but that an appreciable minority would not. A shared decision-making process with full consideration of patient preferences and individualized risk estimates should determine the appropriate course of action. For recommendations regarding modifying risk factors prior to surgery, including BMI, glycemic control, and nicotine dependence, patients should be educated on the increased risk of medical and surgical complications associated with their specific condition. Patients should be counseled on effective methods to modify the risk factors (e.g., weight loss, improved glycemic control, nicotine cessation) and",
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty  American College of Rheumatology      D7E914B32636437769C151DE0A277789 10.1002/acr.24893 Submitted for publication February 9, 2022; accepted in revised form April 7, 2022.  INTRODUCTION Advances in antirheumatic therapy have led to remarkable improvements in treatment and quality of life for people with rheumatic musculoskeletal diseases (RMDs); however, total hip arthroplasty (THA) and total knee arthroplasty (TKA) remain a mainstay of treatment among RMD patients with advanced symptomatic joint damage, most frequently those with inflammatory arthritis (IA), including spondylarthritis (SpA), rheumatoid arthritis (RA), or psoriatic arthritis (PsA), and those with systemic lupus erythematosus (SLE) The optimal strategy for perioperative",
            "disease activity and are likely to be taking immunosuppressant medications at the time of surgery, the management of which was felt to be beyond the scope of this guideline. This was the focus of the 2022 American College of Rheumatology (ACR)/American Association of Hip and Knee Surgeons (AAHKS) Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty METHODS This guideline follows the ACR guideline development process and ACR policy guiding management of conflicts of interest and disclosures https://rheumatology.org/clinicalpractice-guidelines Consensus required ≥70% agreement on both direction (for or against) and strength (strong or conditional) of each recommendation, as per ACR practice. A recommendation could be either in favor of or against the proposed intervention and either strong or conditional. According to GRADE, a recommendation was categorized as strong if the",
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty      32D6EF0B25CDA1FB80B29547C7367EA8 10.1002/acr.24893  This updated guideline addresses the perioperative management of disease modifying medications for adults with rheumatic diseases, specifically inflammatory arthritis (IA) and systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) and total knee arthroplasty (TKA). A panel of rheumatologists, orthopaedic surgeons, and infectious disease specialists updated the systematic literature review and included currently available medications for the clinically relevant population, intervention, comparator, and outcomes (PICO) questions, updating the 2017 recommendations*. As patients with IA and SLE are at increased risk of infection after THA and TKA, these",
            "arthritis (RA) in this guideline, which is a limitation but was beyond our scope, as questions regarding the timing of surgery in patients who have RA prioritize medication management to decrease infection risk, which was the focus of the updated 2022 ACR/AAHKS Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty This guideline has several strengths. The recommendations were made and voted on by a multidisciplinary collaboration group of orthopedic surgeons, rheumatologists, and patients who have undergone or are scheduled to undergo elective TJA who provided their expertise and insights. In addition, the GRADE methodology is well validated and was utilized to make these consensus-based recommendations In conclusion, this guideline provides evidence-based recommendations regarding the optimal timing of elective TJA in patients who have symptomatic moderate-to-severe OA or"
        ]
    },
    {
        "pregunta": "3. Which disease-modifying antirheumatic drugs (DMARDs) are conditionally recommended to be continued through surgery for patients with RA, AS, PsA, JIA, or SLE undergoing elective THA or TKA?",
        "respuesta": "The 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline conditionally recommends continuing the usual dosing of the following disease-modifying antirheumatic drugs (DMARDs) through surgery for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), or systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA): methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and apremilast.",
        "contexto": [
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty      32D6EF0B25CDA1FB80B29547C7367EA8 10.1002/acr.24893  This updated guideline addresses the perioperative management of disease modifying medications for adults with rheumatic diseases, specifically inflammatory arthritis (IA) and systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) and total knee arthroplasty (TKA). A panel of rheumatologists, orthopaedic surgeons, and infectious disease specialists updated the systematic literature review and included currently available medications for the clinically relevant population, intervention, comparator, and outcomes (PICO) questions, updating the 2017 recommendations*. As patients with IA and SLE are at increased risk of infection after THA and TKA, these",
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty  American College of Rheumatology      D7E914B32636437769C151DE0A277789 10.1002/acr.24893 Submitted for publication February 9, 2022; accepted in revised form April 7, 2022.  INTRODUCTION Advances in antirheumatic therapy have led to remarkable improvements in treatment and quality of life for people with rheumatic musculoskeletal diseases (RMDs); however, total hip arthroplasty (THA) and total knee arthroplasty (TKA) remain a mainstay of treatment among RMD patients with advanced symptomatic joint damage, most frequently those with inflammatory arthritis (IA), including spondylarthritis (SpA), rheumatoid arthritis (RA), or psoriatic arthritis (PsA), and those with systemic lupus erythematosus (SLE) The optimal strategy for perioperative",
            "<ul>\n<li>RA = rheumatoid arthritis; AS = ankylosing spondylitis; PsA = psoriatic arthritis; JIA = juvenile idiopathic arthritis; DMARDs = disease-modifying antirheumatic drugs; TJA = total joint arthroplasty.</li>\n</ul>\n\n<p>† Apremilast is a change from the prior recommendation.</p>\n\n<p>‡ Indicates a change from the prior recommendation.</p>",
            "<h1>RESULTS/RECOMMENDATIONS</h1>\n\n<h1>Table 3. Recommendations for perioperative management of anti-rheumatic drug therapy in patients with inflammatory arthritis and those with systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA)*</h1>",
            "no recommendation achieved <80% of the vote, and 4 of the votes were unanimous. 2. For each recommendation, a summary of the supporting evidence or conditions is provided. 3. Therapies that were approved after the end of the original systematic literature review on March 6, 2016 through August 2021 are included in these updated recommendations. Therapies approved after the end of the updated systematic review (March 6, 2016 to August 26, 2021) are not included in these recommendations. 4. PICO questions were combined in the final recommendations for clarity. Recommendations For patients with RA, AS, PsA, JIA, or all SLE undergoing elective THA or TKA, continuing the usual dosing of the following disease-modifying antirheumatic drugs (DMARDs) through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast. This conditional recommendation now includes apremilast, but it is otherwise unchanged from the 2017 guideline. Four"
        ]
    },
    {
        "pregunta": "4. What is the recommendation for withholding biologics, including rituximab, prior to surgery for patients with RA, AS, PsA, or JIA undergoing elective THA or TKA?",
        "respuesta": "The 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline conditionally recommends withholding all biologics, including rituximab, prior to surgery for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), or juvenile idiopathic arthritis (JIA) undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA). The guideline suggests planning the surgery after the next dose of the biologic is due. This recommendation is based on low-level evidence and aims to balance the risk of disease flare when medications are withheld with the risk of infection attributed to the medications if they are continued.",
        "contexto": [
            "and/or apremilast. This conditional recommendation now includes apremilast, but it is otherwise unchanged from the 2017 guideline. Four observational studies provided additional indirect evidence to the previous systematic literature review and found no relationship between the included drugs and the risk of postoperative infections, although the number of included cases and events were low For patients with RA, AS, PsA, or JIA undergoing elective THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended. This recommendation no longer includes patients with SLE, who are addressed separately (see below for rationale) but has not otherwise changed. Table 2 This recommendation is conditional because the evidence is indirect and there is a lack of a comparator group in the included studies Low For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving glucocorticoids",
            "<p>|Recommendation/strength of recommendation|Level of evidence|\n|---|---|\n|For patients with RA, AS, PsA, JIA, or all SLE undergoing THA or TKA, continuing the usual dosing of the following DMARDs through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast.†|Low to moderate|\n|For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended.|Low|\n|For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding tofacitinib, baricitinib, and upadacitinib for at least 3 days prior to surgery is conditionally recommended.‡|Low|\n|For patients with SLE (not severe) undergoing THA or TKA, withholding the current dose of mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, mizoribine, or tacrolimus 1 week prior to surgery is conditionally recommended.|Low|",
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty  American College of Rheumatology      D7E914B32636437769C151DE0A277789 10.1002/acr.24893 Submitted for publication February 9, 2022; accepted in revised form April 7, 2022.  INTRODUCTION Advances in antirheumatic therapy have led to remarkable improvements in treatment and quality of life for people with rheumatic musculoskeletal diseases (RMDs); however, total hip arthroplasty (THA) and total knee arthroplasty (TKA) remain a mainstay of treatment among RMD patients with advanced symptomatic joint damage, most frequently those with inflammatory arthritis (IA), including spondylarthritis (SpA), rheumatoid arthritis (RA), or psoriatic arthritis (PsA), and those with systemic lupus erythematosus (SLE) The optimal strategy for perioperative",
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty      32D6EF0B25CDA1FB80B29547C7367EA8 10.1002/acr.24893  This updated guideline addresses the perioperative management of disease modifying medications for adults with rheumatic diseases, specifically inflammatory arthritis (IA) and systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) and total knee arthroplasty (TKA). A panel of rheumatologists, orthopaedic surgeons, and infectious disease specialists updated the systematic literature review and included currently available medications for the clinically relevant population, intervention, comparator, and outcomes (PICO) questions, updating the 2017 recommendations*. As patients with IA and SLE are at increased risk of infection after THA and TKA, these",
            "for the perioperative management of DMARDs, biologics, and GCs for adult patients with RA, SpA including AS and PsA, JIA, and SLE undergoing elective THA or TKA. This guideline is intended for use by clinicians and patients and balances the risk of flares of disease when medications are withheld versus infection risk attributed to the medications when they are continued. This update adds new medications introduced and reviews the studies published since the 2017 ACR/AAHKS guideline that have informed our recommendations. The scope of the guideline has not changed and addresses when to withhold and when to restart disease-modifying therapies, as well as perioperative GC management. Although we included patients in our Voting Panel, we did not reinstate the Patient Panel due to the risk associated with the COVID-19 pandemic, and because we thought it was unlikely that patients' priorities regarding the risk of flare versus the risk of infection would have changed. The updated medication"
        ]
    },
    {
        "pregunta": "5. How should glucocorticoid therapy be managed for patients with RA, AS, PsA, or SLE undergoing THA or TKA?",
        "respuesta": "For patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), or systemic lupus erythematosus (SLE) undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA) who are receiving glucocorticoids, the 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline conditionally recommends continuing their current daily dose of glucocorticoids rather than administering supraphysiologic (\"stress dose\") glucocorticoids on the day of surgery. This recommendation is consistent with the previous guideline and is based on the consideration of available evidence, recognizing that high doses of glucocorticoids have not been shown to significantly affect outcomes in these patients within the context of THA or TKA.",
        "contexto": [
            "rheumatoid arthritis (RA), or psoriatic arthritis (PsA), and those with systemic lupus erythematosus (SLE) The optimal strategy for perioperative medication management remains unknown, but antirheumatic therapy is a readily modifiable risk factor for infection, whereas other risk factors for adverse outcomes, including disease activity or severity or longterm glucocorticoid (GC) use, may not be modifiable Given the increased infection risk seen in patients with IA and patients with SLE undergoing these procedures, the existing evidence base used to guide our recommendations, the time afforded by these elective procedures to manage medications, and the frequent use of these procedures in patients with IA or SLE While the principles surrounding these recommendations may be extrapolated and applied to other surgical procedures, it should be noted that the evidence and consensus used to inform this guideline were drawn primarily from orthopedic literature. As in the prior version, this",
            "<h1>RESULTS/RECOMMENDATIONS</h1>\n\n<h1>Table 3. Recommendations for perioperative management of anti-rheumatic drug therapy in patients with inflammatory arthritis and those with systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA)*</h1>",
            "postoperative complications led to delays in restarting therapy Patients and their physicians might elect longer periods of not taking medication given a history of prior severe infections or a history of a prior prosthetic joint infection. For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving GCs for their rheumatic condition, continuing their current daily dose of GCs rather than administering supraphysiologic doses of GCs on the day of surgery is conditionally recommended. This recommendation is unchanged from the previous guideline, with 2 new studies considered. One study found no significant association of supraphysiologic (\"stress dose\") GC doses with adverse events in SLE patients undergoing THA or TKA, but the sizes of the patient groups were small DISCUSSION We have updated the 2017 ACR/AAHKS guideline for the perioperative management of DMARDs, biologics, and GCs for adult patients with RA, SpA including AS and PsA, JIA, and SLE undergoing",
            "of a comparator group in the included studies Low For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving glucocorticoids for their rheumatic condition, continuing their current daily dose of glucocorticoids rather than administering supraphysiologic doses of glucocorticoids on the day of surgery is conditionally recommended. surgery, although patients receiving intravenous abatacept within 2 weeks of surgery (one-half of a dosing interval) had a numerically higher rate of adverse events that was not statistically significant Planning the surgery after the end of the dose interval was favored because active drug levels would be low. For example, for rituximab, dosed every 6 months, surgery should be planned during month 7, and for adalimumab, dosed every 2 weeks, surgery should be planned for week 3 (see Table 2 For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding tofacitinib, baricitinib, and upadacitinib for at least 3 days prior to",
            "(PICO) questions, updating the 2017 recommendations*. As patients with IA and SLE are at increased risk of infection after THA and TKA, these recommendations aim to balance the risk of perioperative infection and the risk of disease flares, recognizing that all flares have an impact on quality of life but a flare in a patient with severe SLE at risk for organ damage warrants unique considerations. This updated guideline includes recently introduced immunosuppressive medications to help decision-making by clinicians and patients regarding perioperative disease modifying medication management for patients with IA and SLE at the time of elective THA or TKA. ***For patients with RA, AS, PsA, or all SLE for whom anti-rheumatic therapy was held prior to undergoing TJA, restarting the anti-rheumatic therapy once the wound shows evidence of healing, any sutures/staples are out, there is no significant swelling, erythema or drainage, and there is no ongoing non-surgical site infection, which"
        ]
    },
    {
        "pregunta": "6. What is the updated recommendation for withholding tofacitinib, baricitinib, and upadacitinib prior to surgery for patients with RA, AS, PsA, or JIA undergoing THA or TKA?",
        "respuesta": "The updated recommendation for withholding tofacitinib, baricitinib, and upadacitinib prior to surgery for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), or juvenile idiopathic arthritis (JIA) undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA) is to withhold these medications for at least 3 days before surgery. This change from the previous guideline is based on trial data indicating rapid increases in disease activity after interrupting tofacitinib therapy, suggesting a quick reversal of the immunosuppressive effects, thereby informing the revised recommendation.",
        "contexto": [
            "<p>|Recommendation/strength of recommendation|Level of evidence|\n|---|---|\n|For patients with RA, AS, PsA, JIA, or all SLE undergoing THA or TKA, continuing the usual dosing of the following DMARDs through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast.†|Low to moderate|\n|For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended.|Low|\n|For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding tofacitinib, baricitinib, and upadacitinib for at least 3 days prior to surgery is conditionally recommended.‡|Low|\n|For patients with SLE (not severe) undergoing THA or TKA, withholding the current dose of mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, mizoribine, or tacrolimus 1 week prior to surgery is conditionally recommended.|Low|",
            "2 For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding tofacitinib, baricitinib, and upadacitinib for at least 3 days prior to surgery is conditionally recommended. This conditional recommendation was changed from the prior guideline. For the previous guideline, while the short serum half-life of tofacitinib was known, concern for a longer duration of the immune effect prompted the recommendation to withhold tofacitinib for 7 days prior to surgery. The new recommendation was informed by trial data demonstrating rapid increases in disease activity after interrupting tofacitinib therapy, suggesting a rapid reversal of the immunosuppressive effects, so the recommendation was changed to withhold tofacitinib for 3 days prior to surgery For patients with SLE (not severe) undergoing THA or TKA, withholding the current dose of mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, mizoribine, or tacrolimus 1 week prior to surgery is conditionally",
            "and/or apremilast. This conditional recommendation now includes apremilast, but it is otherwise unchanged from the 2017 guideline. Four observational studies provided additional indirect evidence to the previous systematic literature review and found no relationship between the included drugs and the risk of postoperative infections, although the number of included cases and events were low For patients with RA, AS, PsA, or JIA undergoing elective THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended. This recommendation no longer includes patients with SLE, who are addressed separately (see below for rationale) but has not otherwise changed. Table 2 This recommendation is conditional because the evidence is indirect and there is a lack of a comparator group in the included studies Low For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving glucocorticoids",
            "thought it was unlikely that patients' priorities regarding the risk of flare versus the risk of infection would have changed. The updated medication list includes medications introduced to treat RA and SpA, including AS and PsA. We have included perioperative management recommendations for the recently introduced JAK-targeted therapies, baricitinib and upadacitinib, in addition to tofacitinib. We have included new management recommendations for the interleukin-17 (IL-17) blocking agent ixekizumab, the IL-23blocking drug, guselkumab, and the novel synthetic DMARD apremilast. Anifrolumab, approved by the FDA on July 30, 2021, and voclosporin, approved January 22, 2021, were included in this guideline, although there is no information regarding their use in the perioperative period. They increase the risk of infection, and therefore the use of these medications in patients with severe SLE would merit review by the treating rheumatologist in consideration of surgery. The Voting Panel",
            "<h1>RESULTS/RECOMMENDATIONS</h1>\n\n<h1>Table 3. Recommendations for perioperative management of anti-rheumatic drug therapy in patients with inflammatory arthritis and those with systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA)*</h1>"
        ]
    },
    {
        "pregunta": "7. What medications are conditionally recommended to be withheld for patients with SLE (not severe) undergoing THA or TKA?",
        "respuesta": "For patients with non-severe systemic lupus erythematosus (SLE) undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA), the following medications are conditionally recommended to be withheld:\n\n1. Mycophenolate mofetil\n2. Mycophenolic acid\n3. Azathioprine\n4. Cyclosporine\n5. Mizoribine\n6. Tacrolimus\n7. Belimumab\n8. Rituximab\n\nThese medications are to be withheld prior to surgery as per the guideline recommendations.",
        "contexto": [
            "|For patients with SLE (not severe) undergoing THA or TKA, withholding the usual dose of belimumab and rituximab prior to surgery is conditionally recommended.|Low|\n|For patients with severe SLE who have been deemed appropriate to undergo THA or TKA, continuing the usual dose of mycophenolate mofetil, mycophenolic acid (Myfortic), azathioprine, mizoribine, cyclosporine, or tacrolimus, anifrolumab, and voclosporin through surgery is conditionally recommended.‡|Low|\n|For patients with severe SLE undergoing THA or TKA, continuing belimumab and planning surgery in the last month of the dosing cycle of rituximab is conditionally recommended.‡|Low|",
            "<h1>RESULTS/RECOMMENDATIONS</h1>\n\n<h1>Table 3. Recommendations for perioperative management of anti-rheumatic drug therapy in patients with inflammatory arthritis and those with systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA)*</h1>",
            "<p>|Recommendation/strength of recommendation|Level of evidence|\n|---|---|\n|For patients with RA, AS, PsA, JIA, or all SLE undergoing THA or TKA, continuing the usual dosing of the following DMARDs through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast.†|Low to moderate|\n|For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended.|Low|\n|For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding tofacitinib, baricitinib, and upadacitinib for at least 3 days prior to surgery is conditionally recommended.‡|Low|\n|For patients with SLE (not severe) undergoing THA or TKA, withholding the current dose of mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, mizoribine, or tacrolimus 1 week prior to surgery is conditionally recommended.|Low|",
            "dose of mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, mizoribine, or tacrolimus 1 week prior to surgery is conditionally recommended. This recommendation remains unchanged from the prior guideline. Patients with frequent flares or SLE that is difficult to control might continue their medications, but the majority could be followed up closely after surgery to address a flare. For patients with SLE (not severe) undergoing THA or TKA, withholding the usual dose of belimumab and rituximab prior to surgery is conditionally recommended. This recommendation is unchanged from the prior guideline. Patients with SLE that is not severe would not be at risk for permanent organ damage should they flare. In addition, nonsevere SLE patients could be followed up closely after surgery, and an intervention could be made to treat a flare as needed. Patients with frequent flares or SLE that is difficult to control might choose to continue their medications in a shared",
            "and/or apremilast. This conditional recommendation now includes apremilast, but it is otherwise unchanged from the 2017 guideline. Four observational studies provided additional indirect evidence to the previous systematic literature review and found no relationship between the included drugs and the risk of postoperative infections, although the number of included cases and events were low For patients with RA, AS, PsA, or JIA undergoing elective THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended. This recommendation no longer includes patients with SLE, who are addressed separately (see below for rationale) but has not otherwise changed. Table 2 This recommendation is conditional because the evidence is indirect and there is a lack of a comparator group in the included studies Low For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving glucocorticoids"
        ]
    },
    {
        "pregunta": "8. What is the recommendation for patients with severe SLE undergoing THA or TKA regarding the continuation of belimumab and rituximab?",
        "respuesta": "For patients with severe systemic lupus erythematosus (SLE) undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA), the continuation of belimumab is conditionally recommended. Additionally, it is conditionally recommended to plan the surgery in the last month of the rituximab dosing cycle. This recommendation takes into account the long dosing interval of rituximab, and it aims to avoid disruptions of therapy. Typically, for patients receiving rituximab every 6 months, surgery should be scheduled during month 5 or 6 of the dosing cycle.",
        "contexto": [
            "|For patients with SLE (not severe) undergoing THA or TKA, withholding the usual dose of belimumab and rituximab prior to surgery is conditionally recommended.|Low|\n|For patients with severe SLE who have been deemed appropriate to undergo THA or TKA, continuing the usual dose of mycophenolate mofetil, mycophenolic acid (Myfortic), azathioprine, mizoribine, cyclosporine, or tacrolimus, anifrolumab, and voclosporin through surgery is conditionally recommended.‡|Low|\n|For patients with severe SLE undergoing THA or TKA, continuing belimumab and planning surgery in the last month of the dosing cycle of rituximab is conditionally recommended.‡|Low|",
            "noted in the previous guideline, the patient's rheumatologist should be consulted regarding medication management. A patient with severe SLE who has been stable for >6 months or who has a history of recurrent or severe infections might discontinue the medications in the perioperative period. For patients with severe SLE undergoing THA or TKA, continuing belimumab and planning surgery in the last month of the dosing cycle of rituximab is conditionally recommended. In the prior guideline, rituximab was included in the recommendations with other biologics, but increased use for SLE treatment, the long dosing interval for rituximab, and the indication of belimumab as therapy for severe SLE manifestations has informed this change. Surgery should be planned at the end of the dosing cycle, typically during month 5 or 6 for patients receiving rituximab every 6 months, and to avoid disruptions of therapy rather than wait longer, given the long dosing interval for rituximab. The panel noted",
            "rituximab every 6 months, and to avoid disruptions of therapy rather than wait longer, given the long dosing interval for rituximab. The panel noted that rituximab is used in SLE without an indication approved by the US Food and Drug Administration (FDA) but also noted that it has been included in SLE treatment guidelines This recommendation has changed since the prior guideline in part because of the additional indication for the use of belimumab in severe SLE including nephritis, as well as increased comfort with belimumab among clinicians and patients given its widespread use, low infection risk described in clinical trials, and inclusion in SLE treatment guidelines For patients with RA, AS, PsA, or all SLE for whom antirheumatic therapy was withheld prior to undergoing total joint arthroplasty, antirheumatic therapy should be restarted once the wound shows evidence of healing, any sutures/ staples are out, there is no significant swelling, erythema, or drainage, and there is no",
            "<h1>RESULTS/RECOMMENDATIONS</h1>\n\n<h1>Table 3. Recommendations for perioperative management of anti-rheumatic drug therapy in patients with inflammatory arthritis and those with systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA)*</h1>",
            "dose of mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, mizoribine, or tacrolimus 1 week prior to surgery is conditionally recommended. This recommendation remains unchanged from the prior guideline. Patients with frequent flares or SLE that is difficult to control might continue their medications, but the majority could be followed up closely after surgery to address a flare. For patients with SLE (not severe) undergoing THA or TKA, withholding the usual dose of belimumab and rituximab prior to surgery is conditionally recommended. This recommendation is unchanged from the prior guideline. Patients with SLE that is not severe would not be at risk for permanent organ damage should they flare. In addition, nonsevere SLE patients could be followed up closely after surgery, and an intervention could be made to treat a flare as needed. Patients with frequent flares or SLE that is difficult to control might choose to continue their medications in a shared"
        ]
    },
    {
        "pregunta": "9. When should antirheumatic therapy be restarted for patients with RA, AS, PsA, or SLE who underwent total joint arthroplasty?",
        "respuesta": "Antirheumatic therapy should be restarted for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), or systemic lupus erythematosus (SLE) following total joint arthroplasty once the wound shows evidence of healing, all sutures or staples are removed, there is no significant swelling, erythema, or drainage, and there is no ongoing nonsurgical site infection. This is typically around 14 days post-surgery.",
        "contexto": [
            "|For patients with RA, AS, PsA, or all SLE for whom antirheumatic therapy was withheld prior to undergoing TJA, antirheumatic therapy should be restarted once the wound shows evidence of healing, any sutures/staples are out, there is no significant swelling, erythema, or drainage, and there is no ongoing nonsurgical site infection, which is typically ~14 days, is conditionally recommended.|Low|\n|For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving glucocorticoids for their rheumatic condition, continuing their current daily dose of glucocorticoids rather than administering supraphysiologic doses of glucocorticoids on the day of surgery is conditionally recommended.|Low|</p>",
            "<p>† Recommendation that has changed since 2017.</p>\n\n<p>‡ Severe SLE indicates organ-threatening disease.</p>\n\n<p>§ Drug added for 2022 update.</p>\n\n<p>¶ For patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or all SLE for whom antirheumatic therapy was withheld prior to undergoing total joint arthroplasty, antirheumatic therapy should be restarted once the wound shows evidence of healing, any sutures/staples are out, there is no signiﬁcant swelling, erythema, or drainage, and there is no ongoing nonsurgical site infection, which is typically ~14 days.</p>\n\n<h1>Recommendation pertains to infection risk and does not account for risk of cardiac events or venous thromboembolism.</h1>\n\n<h1>RESULTS/RECOMMENDATIONS</h1>",
            "<ul>\n<li>RA = rheumatoid arthritis; AS = ankylosing spondylitis; PsA = psoriatic arthritis; JIA = juvenile idiopathic arthritis; DMARDs = disease-modifying antirheumatic drugs; TJA = total joint arthroplasty.</li>\n</ul>\n\n<p>† Apremilast is a change from the prior recommendation.</p>\n\n<p>‡ Indicates a change from the prior recommendation.</p>",
            "rheumatoid arthritis (RA), or psoriatic arthritis (PsA), and those with systemic lupus erythematosus (SLE) The optimal strategy for perioperative medication management remains unknown, but antirheumatic therapy is a readily modifiable risk factor for infection, whereas other risk factors for adverse outcomes, including disease activity or severity or longterm glucocorticoid (GC) use, may not be modifiable Given the increased infection risk seen in patients with IA and patients with SLE undergoing these procedures, the existing evidence base used to guide our recommendations, the time afforded by these elective procedures to manage medications, and the frequent use of these procedures in patients with IA or SLE While the principles surrounding these recommendations may be extrapolated and applied to other surgical procedures, it should be noted that the evidence and consensus used to inform this guideline were drawn primarily from orthopedic literature. As in the prior version, this",
            "no recommendation achieved <80% of the vote, and 4 of the votes were unanimous. 2. For each recommendation, a summary of the supporting evidence or conditions is provided. 3. Therapies that were approved after the end of the original systematic literature review on March 6, 2016 through August 2021 are included in these updated recommendations. Therapies approved after the end of the updated systematic review (March 6, 2016 to August 26, 2021) are not included in these recommendations. 4. PICO questions were combined in the final recommendations for clarity. Recommendations For patients with RA, AS, PsA, JIA, or all SLE undergoing elective THA or TKA, continuing the usual dosing of the following disease-modifying antirheumatic drugs (DMARDs) through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast. This conditional recommendation now includes apremilast, but it is otherwise unchanged from the 2017 guideline. Four"
        ]
    },
    {
        "pregunta": "10. What is the recommendation for managing glucocorticoid therapy on the day of surgery for patients with RA, AS, PsA, or SLE undergoing THA or TKA?",
        "respuesta": "The 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline conditionally recommends continuing the current daily dose of glucocorticoids on the day of surgery for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), or systemic lupus erythematosus (SLE) undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA). It does not recommend administering supraphysiologic (\"stress dose\") glucocorticoids, as this has not been shown to significantly affect outcomes in these patients within the context of these surgeries.",
        "contexto": [
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty      32D6EF0B25CDA1FB80B29547C7367EA8 10.1002/acr.24893  This updated guideline addresses the perioperative management of disease modifying medications for adults with rheumatic diseases, specifically inflammatory arthritis (IA) and systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) and total knee arthroplasty (TKA). A panel of rheumatologists, orthopaedic surgeons, and infectious disease specialists updated the systematic literature review and included currently available medications for the clinically relevant population, intervention, comparator, and outcomes (PICO) questions, updating the 2017 recommendations*. As patients with IA and SLE are at increased risk of infection after THA and TKA, these",
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty  American College of Rheumatology      D7E914B32636437769C151DE0A277789 10.1002/acr.24893 Submitted for publication February 9, 2022; accepted in revised form April 7, 2022.  INTRODUCTION Advances in antirheumatic therapy have led to remarkable improvements in treatment and quality of life for people with rheumatic musculoskeletal diseases (RMDs); however, total hip arthroplasty (THA) and total knee arthroplasty (TKA) remain a mainstay of treatment among RMD patients with advanced symptomatic joint damage, most frequently those with inflammatory arthritis (IA), including spondylarthritis (SpA), rheumatoid arthritis (RA), or psoriatic arthritis (PsA), and those with systemic lupus erythematosus (SLE) The optimal strategy for perioperative",
            "rheumatoid arthritis (RA), or psoriatic arthritis (PsA), and those with systemic lupus erythematosus (SLE) The optimal strategy for perioperative medication management remains unknown, but antirheumatic therapy is a readily modifiable risk factor for infection, whereas other risk factors for adverse outcomes, including disease activity or severity or longterm glucocorticoid (GC) use, may not be modifiable Given the increased infection risk seen in patients with IA and patients with SLE undergoing these procedures, the existing evidence base used to guide our recommendations, the time afforded by these elective procedures to manage medications, and the frequent use of these procedures in patients with IA or SLE While the principles surrounding these recommendations may be extrapolated and applied to other surgical procedures, it should be noted that the evidence and consensus used to inform this guideline were drawn primarily from orthopedic literature. As in the prior version, this",
            "<h1>RESULTS/RECOMMENDATIONS</h1>\n\n<h1>Table 3. Recommendations for perioperative management of anti-rheumatic drug therapy in patients with inflammatory arthritis and those with systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA)*</h1>",
            "disease activity and are likely to be taking immunosuppressant medications at the time of surgery, the management of which was felt to be beyond the scope of this guideline. This was the focus of the 2022 American College of Rheumatology (ACR)/American Association of Hip and Knee Surgeons (AAHKS) Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty METHODS This guideline follows the ACR guideline development process and ACR policy guiding management of conflicts of interest and disclosures https://rheumatology.org/clinicalpractice-guidelines Consensus required ≥70% agreement on both direction (for or against) and strength (strong or conditional) of each recommendation, as per ACR practice. A recommendation could be either in favor of or against the proposed intervention and either strong or conditional. According to GRADE, a recommendation was categorized as strong if the"
        ]
    }
]